Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells

https://doi.org/10.1016/0922-4106(95)90037-3Get rights and content

Abstract

Two splice variants of the pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor (PACAP receptor and PACAP/HOP receptor isoform) were stably expressed in Chinese hamster ovary (CHO) cells that did not express constitutively receptors for this family. The PACAP./HOP receptor protein had a 28 amino acis extension in the C-terminal part of the third intracellular loop. The two cell lines studied, CHO 2–10 (PACAP receptor) and CHO 4–12 (PACAP/HOP receptor) expressed a receptor density of 4.6±0.3 and 2.6±0.2 pmol/mg protein, respectively, with corresponding Kd values of 14.2±2.0 and 8.2±1.0 nM for [Ac-His1]PACAP-27 used as a tracer. Tracer binding was slightly decreased by GTP in both clones. The Kd values of PACAP-27, PACAP-38, vasoactive intestinal peptide (VIP), PACAP-27 fragments and analogues evaluated by binding competition curves, were higher in CHO 2–10 than in CHO 4–12, whereas the Kd for PACAP-38 fragments did not differ. The receptors were coupled to adenylate cyclase and the EC50 values were lower than the Kd values in both cell lines, suggesting an amplification process due to the existence of spare receptors. Pretreatment of the CHO 4–12 cells with increasing concentrations of PACAP-27 for 24 h induced an increase in the Kact values and a decrease in the maximal stimulation; the same pretreatment of CHO 2–10 cells also induced an increase in the Kact values, but a marked increase in the adenylate cyclase activity in the absence of added peptide, suggesting that PACAP pretreatment had induced a permanent coupling of the receptor to the Gs site. Thus, the two splice variants differed in their capacity to recognize the ligand, and in their coupling to the Gs sites.

References (26)

  • T. Ishihara et al.

    Molecular cloning and expression of a cDNA encoding the secretin receptor

    EMBO J.

    (1991)
  • L.J. Jelinek et al.

    Expression cloning and signaling properties of the rat glucagon receptor

    Science

    (1993)
  • H. Jüppner et al.

    A G protein-like receptor for parathyroid hormone and parathyroid hormone-related peptide

    Science

    (1991)
  • Cited by (41)

    • C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor

      2016, Peptides
      Citation Excerpt :

      PACAP, the endogenous agonist of the PAC1 receptor, exists in vivo as either a 27 or 38 residue peptide (PACAP-27 or -38), depending on extent of processing of its prohormone precursor (Fig. 1). To confirm that these two forms of PACAP are similar in both potency and intrinsic activity at the PAC1 receptor in a cell-based assay, as previously established in cell-free receptor binding assays [7], we examined PACAP-induced cyclic AMP elevation in neuroendocrine cell line NS-1 that natively expresses PAC1 receptors but do not express the highly homologous VPAC1 or VPAC2 receptors [15]. For real-time measurements of cyclic AMP production, NS-1 cells were transduced with a retroviral vector encoding a cAMP biosensor (CBS) that catalyzes the oxidization of luciferin to yield a luminescent signal that is proportional to cAMP levels.

    • A combination assay for simultaneous assessment of multiple signaling pathways

      1999, Journal of Pharmacological and Toxicological Methods
    View all citing articles on Scopus
    View full text